Figure 3.

Tongue and esophageal hyperplasia and inflammation in mice treated chronically with anti-TGF-β. Tongue and esophageal sections from BALB/c and RAG-2KO mice that were treated three times a week for 12 weeks with either 50 or 5 mg/kg of anti-TGF-β or control mAb were scored by a veterinary pathologist according to the criteria outlined in Table 2. Graphs represent scores of individual mice in each treatment group for tongue hyperplasia (A), tongue inflammation (B), esophageal hyperplasia (C), and esophageal inflammation (D). Means of the data are also indicated.